H ip resurfacing, or surface replacement arthroplasty, has been performed for approximately 15 years in Europe and Australia, predominantly by surgeons who received specific training in this technically demanding procedure. 1, 2 Proposed advantages of surface replacement arthroplasty vs total hip arthroplasty (THA) include bone preservation and physiologic loading of the proximal femur, avoidance of femoral canal reaming and potential embolization, improved stability of the implant, decreased thigh pain, and surgeons' willingness to allow patients to return to higherdemand activities. [2] [3] [4] [5] [6] In May 2006, the US Food and Drug Administration approved the first metal-on-metal resurfacing device for use in the United States, the Birmingham Hip Resurfacing (BHR) system (Smith & Nephew, Memphis, Tennessee). Because of the potential advantages of surface replacement arthroplasty, widespread use of the BHR system and other surface replacement arthroplasty designs began soon after approval of these devices by surgeons with varying degrees of experience with hip arthroplasty and the surgical technique. However, this initial enthusiasm was tempered by recent reports of increased complications, such as femoral neck fracture, metal-on-metal bearing surface wear and potential adverse tissue reaction, and decreased implant survivorship compared with primary THA. [7] [8] [9] [10] [11] National joint registries in Australia, England and Wales, and Sweden confirmed the presence of higher revision rates after surface replacement arthroplasty vs primary THA. [12] [13] [14] In the National Joint Registry for England and Wales, the BHR implant had a revision rate of 1.1% at 1 year, 2.4% at 3 years, and 5.1% at 7 years. 13 Similarly, data from the Australian Orthopaedic Association National Joint Replacement Registry showed a 1.4% cumulative revision rate for the BHR implant at 1 year, a rate of 2.5% at 3 years, and a rate of 7.1% at 11 years, although results in men younger than 65 years showed a lower revision rate than that for primary THA.
12 Initial results from the United States included a national safety survey of 449 BHR implants performed by 89 surgeons that noted a 3.1% revision rate at 1-year follow-up. 15 In this initial series, 14 component revisions were performed: 10 for femoral neck fracture, 2 for dislocations, and 2 for acetabular component loosening. 15 However, a separate analysis of the first 650 BHR implants performed by 5 surgeons specializing in hip arthroplasty noted a lower revision rate of 1.1% at 1-year follow-up. 16 The complication rate noted in this series of BHR implants performed by hip specialists was equivalent to that reported for primary THA. 16 Numerous studies have tried to elucidate the risk factors for early revision after surface replacement arthroplasty. Risk factors that were investigated included sex, 17 age, 2,18 metal ion release, 8, 19, 20 component rotation and migration, 21 and component size. 22 Several centers reported excellent 10-year survival rates of 95% to 98% in men, showing the effect of patient sex and relative component size on implant survivorship. [23] [24] [25] However, although these studies identified potential patientand implant-related risk factors, they did not consider the role of the surgeon in the risk of revision. Proper implant positioning of both the acetabular and femoral components is the key to success in surface replacement arthroplasty, which can be technically challenging. In a review of their first 200 surface replacement arthroplasty procedures, Amstutz et al 26 showed that acetabular component orientation was the only variable associated with component revision. Langton et al 22 showed that component malpositioning increased the rate of metal ion release. These factors are undoubtedly influenced by surgeon experience with surface replacement arthroplasty. Nunley et al 16 reported a 5.6% complication rate in the first 25 surface replacement arthroplasty procedures performed by hip arthroplasty specialists vs a 1.6% complication rate in the second 25 surface replacement arthroplasty procedures performed.
Previous data on survivorship of the BHR implant came from design surgeons and large national databases outside of the United States.
2,12-14 Few reported outcomes of surface replacement arthroplasty have come from US centers. In an attempt to limit the potential risk of surgeon inexperience with hip arthroplasty, and because the orthopedic literature typically assessed the results of surface replacement arthroplasty performed by hip specialists, this study included BHR system procedures performed by a single surgeon from each of 6 high-volume total joint centers. The goal of this study was to report clinical outcomes, complication rates, and survivorship at 2 to 4 years of follow-up in a consecutive series of BHR implants performed by 6 experienced US high-volume orthopedic surgeons.
Materials and Methods
The authors conducted a multicenter retrospective cohort study of surface replacement arthroplasty procedures performed with the BHR system by a single surgeon from each of 6 high-volume joint reconstruction centers at a minimum of 2 years of follow-up. Of these surgeons, 5 had been in clinical practice for more than 20 years and 1 had been in practice for longer than 5 years during the study period. All surgeons specialized in hip and knee arthroplasty. Patients who underwent the BHR implant procedure between June 1, 2006, and September 1, 2008, were identified for analysis a minimum of 2 years after surgery. Data were collected from March through November 2010 at each of the 6 total joint arthroplasty centers. Patients were considered eligible for a 2-year follow-up visit if they were seen or contacted 21 months after surgery. Patients were not excluded from the study based on sex, body mass index, preoperative diagnosis, or bone quality. A consecutive series of patients, starting with each surgeon's first surface replacement arthroplasty procedure using the BHR implant, was included for analysis. All participating surgeons underwent training with an expert in hip resurfacing and had access to established joint registries and radiographs at their respective centers. None of the surgeons used computer-assisted navigation for component placement. All patients underwent hybrid surface replacement arthroplasty with a hydroxyapatite-on-porous metal uncemented acetabular component and a cemented femoral component.
Medical records were reviewed for the most recent clinical data collected at standard of care office visits with the treating surgeon to record the Harris Hip Score and radiographic findings a minimum of 2 years postoperatively. Patients who did not have a 2-year follow-up clinic visit were contacted by telephone to ask whether they had any major complications, such as fracture, dislocation, nerve injury, pulmonary embolism, symptomatic deep venous thrombosis, component loosening or lack of acetabular ingrowth, pseudotumor formation, chronic pain including iliopsoas irritation, infection, and revision. The authors also obtained a modified Harris Hip Score and asked patients to mail copies of radiographs taken at remote sites to their treating surgeons. Radiographs were reviewed at each center for impending failures, such as femoral neck notching, femoral head avascular necrosis or collapse, and signs of loosening of the acetabular or femoral component.
At the time of data collection, the authors contacted patients who had not had a clinical office visit within 6 months to ask about complications and failures. Readmissions, reoperations, and other complications attributable to the BHR system were recorded.
The authors identified 1271 BHR implants (1257 patients) (11 simultaneous bilateral surface replacement arthroplasty procedures and 3 staged bilateral surface replacement arthroplasty procedures) from the 6 centers that were a minimum of 2 years postoperative at the time of data collection. Of the 1271 hips, 4 known major complications occurred less than 2 years postoperatively in patients who were lost to follow-up. An additional 11 hips had no follow-up since surgery, and 112 hips had follow-up at some point less than 1.8 years after surgery but the patients could not be reached by telephone for this study. However, these patients had no known complications at the time of the last follow-up. Therefore, 1144 hips (90%) with a minimum of 2 years of clinical or radiographic follow-up were available for analysis.
Statistical Analysis
Descriptive statistics were used to review demographic and clinical characteristics for all hips identified. Categorical data were presented with frequency and percentage, and continuous variables were presented with mean and standard deviation. Chi-square analysis or 1-way analysis of variance was used to assess differences between surgeons. All analyses were performed with SAS version 9.2 software (SAS Institute Inc, Cary, North Carolina), with an alpha level of 0.05 considered significant.
results
Of the 1271 BHR implant procedures performed, 75% of patients were men, with a mean age of 52.3±7.9 years at the time of surgery (range, 22-81 years). The preoperative diagnosis was osteoarthritis in 91.7% of cases. Mean length of follow-up was 2.7±0.9 years (range, 1.8-4.2 years) ( Table 1) . One-way analysis of variance showed significant demographic differences between surgeons in patient sex (P<.0001), age (P<.0001), and preoperative diagnosis (P=.005) among the 1271 BHR implant procedures performed ( Table 1) . For all surgeons, median acetabular cup size was 56 mm and median femoral head size was 50 mm. There were 1144 hips from 6 centers with a minimum of 2 years of follow-up (90%) available for clinical or radiographic analysis. Of these, 732 (64%) patients were seen at a clinical office visit, 661 (58%) had a radiograph, and 652 (57%) were contacted by telephone ( Table 2) .
Average Harris Hip Score improved from 55.8±12.1 preoperatively to 97.5±5.5 (P<.0001) at the most recent clinical assessment. Significant differences were noted among surgeons for pre-and postoperative scores (both P<.0001) ( Table 2) . Of all patients reviewed, 25 (2.2%) major complications occurred. Nine (0.8%) of these major complications did not require a revision procedure: 3 late dislocations that were treated with a closed procedure, 3 nerve injuries, 2 fractures, and 1 pseudotumor ( Table 3) . Sixteen (1.4%) revisions were performed at the time of latest follow-up. All revision procedures were conversion to THA and were performed for the following diagnoses: 7 fractures, 3 early dislocations, 3 malpositioned acetabular components with pain (metallosis noted in 1), 1 pseudotumor, 1 infection, and 1 femoral component loosening ( Table 4 ). All revision procedures were performed within the first 200 BHR system procedures performed in this consecutive series of patients. An additional 22 (2.0%) minor complications that did not require revision were reported. The most common were radiographic evidence of possible asymptomatic component loosening (8) and heterotopic ossification (8) ( Table 5) .
discussion
Metal-on-metal surface replacement arthroplasty was reintroduced with proposed advantages that included increased stability vs conventional bearings in THA, preservation of the femoral neck and a portion of the femoral head, optimization of stress transfer to the proximal aspect of the femur, and improved ability to withstand high-impact activities.
27,28 Shortterm worldwide results with the use of a hybrid metal-on-metal hip resurfacing system were encouraging. 6 Registry showed a 5% cumulative revision rate at 8 years of follow-up with the BHR device, 12 although national joint registries showed that cumulative revi- 8, 9, 17, 31, 32 led to a decrease in the popularity of surface replacement arthroplasty. However, previous data on survivorship of the BHR implant came from individual institutions and large national databases outside of the United States. Few reported outcomes of the BHR prosthesis came from US centers. The goal of this study was to report clinical outcomes, complication rates, and survivorship at 2 to 4 years of follow-up in a consecutive series of BHR procedures performed by 6 experienced high-volume orthopedic surgeons in the United States.
The study results showed that, in the hands of experienced arthroplasty surgeons, short-term results with the BHR prosthesis in the United States exceeded those presented in national registry data from England and Wales and Australia.
12,13 At a mean follow-up of 2.7 years, the revision rate in the current study was 1.4%, which compared favorably with the cumulative revision rate for the BHR prosthesis reported in the Australian Orthopaedic Association National Joint Replacement Registry at 3 years (2.5%).
12
Furthermore, the low rate of major (2.2%) and minor (2.0%) complications showed that the BHR prosthesis was relatively safe during the follow-up period. The most common indication for revision in the current series was fracture of the proximal femur (0.6%), which is consistent with a report by Amstutz et al, 33 who noted a prevalence of 0.8% in 600 surface replacement arthroplasty procedures.
All revision procedures were performed in patients who were among the first 200 to undergo BHR implant procedures in this consecutive series of patients. This finding was consistent with the known learning curve associated with the initial use of surface replacement arthroplasty. Surgeon experience can affect the rates of femoral fracture, femoral component loosening, acetabular positioning, and other technical factors known to affect clinical outcomes. 16 Femoral fracture and acetabular malpositioning were the 2 most common reasons for revision in this series, both of which can be attributed to surgical technique. Furthermore, since US Food and Drug Administration approval of the BHR system, indications for sur- Despite current concerns about the use of surface replacement arthroplasty, this study showed that when using a device, such as the BHR, with a good track record, the complication rate can be very low. However, the margin for error is low and the procedure is technically demanding. Because these encouraging results have been achieved by experienced, high-volume arthroplasty surgeons, surface replacement arthroplasty may be a specialty procedure. Furthermore, with more stringent indications for its use, outcomes with the BHR device may be excellent. Murray et al 24 reported a 10-year survival rate of 95% in male hips, with a mean postoperative Oxford Hip Score of 43.
Limitations
The current study had several limitations. One was the retrospective nature of the review. However, the study design allowed the authors to include the results of multiple high-volume arthroplasty surgeons from separate centers. The study also achieved a high percentage of clinical follow-up. A second limitation was the relatively short follow-up period, specifically with increased concerns about pseudotumors and adverse tissue reactions after surface replacement arthroplasty. However, in a study by Pandit et al, 34 almost all patients with pseudotumors and clinical symptoms presented before the 30-month follow-up visit. Furthermore, the authors were diligent in contacting patients who had not had a clinical office visit within 6 months to inquire about recent complications and failures, thus capturing recent symptoms. A third limitation was that only approximately 58% of hips in this study had recent radiographs available for review. Therefore, the radiographic samples may not be representative of the overall cohort. In addition, the authors did not specifically collect or analyze component orientation, which is known to affect the survivorship of surface replacement arthroplasty prostheses. 22, 26 Finally, this study was a retrospective review of multiple surgeons. The surgeons did not necessarily follow the same clinical indications for surface replacement arthroplasty or perioperative protocols. However, because this was the initial series of BHR procedures performed by each of these surgeons, indications for use of this procedure likely have become more stringent since its introduction.
conclusion
This study showed excellent results at 2 to 4 years of clinical follow-up with BHR implants performed by 6 highvolume arthroplasty surgeons at 6 US centers. Complication and revision rates were no higher than those with primary THA, and the incidence of adverse metal reactions was very low. Further studies are needed to determine whether the results achieved at US centers match those reported at longer follow-up from design centers outside of the United States references 10. Kwon 
